- AU$15.80m
- AU$19.47m
Brief: Imugene Granted India Patent For Oncolytic Virotherapy CF33
Brief: Imugene Says Oncarlytics Patent Allowance In China
Brief: Imugene Receives A$20 Mln For Convertible Notes Issue
Australia's Imugene hits 2-week high on FDA orphan status for cancer treatment
Brief: Imugene Ltd Says Received US FDA Orphan Drug Designation For Vaxinia
Aussie healthcare stocks set to log modest gains in first-half 2024
Brief: Imugene And Kincell Bio Announce Strategic Partnership
Australia's Imugene drops on plans to sell North Carolina manufacturing facility
Brief: Bile Tract Cancer Expansion Study Opens Following Clearance Of Imugene’S Mast Trial High Dose Cohort
Brief: Imugene Says Oncolytic Virotherapy CF33 Patent Granted
Australia's Imugene rises on China patent for its virus-based cancer therapy
Australia's Arovella Therapeutics falls on ending collaboration with Imugene
Brief: Arovella Therapeutics Gives ALA-101 And Oncarlytics Collaboration Update
Brief: Imugene Ltd Says HY Net Loss Attributable A$68.7 Million
MaxCyte rises on collaboration with Imugene for cancer medicines
Precision BioSciences rises on license deal to develop cancer therapy
Brief: Imugene Says Co And Neoimmunetech To Improve Cancer Treatments
Brief: Imugene Says Europe Patent To Be Granted For Pd1-Vaxx Cancer Vaccine
Australia's Imugene jumps on cancer trial FDA progress